Product Code: DIMI1314
DelveInsight's 'Brain Cancer - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the brain cancer, historical and forecasted epidemiology as well as the brain cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The brain cancer market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM brain cancer market size from 2018 to 2030. The report also covers current brain cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2018-2030.
Brain Cancer Disease Understanding and Treatment Algorithm
Brain Cancer Overview
A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases that have in common the abnormal development of mass lesions in the brain, spinal cord or its coverings. A brain tumor can be classified into two main groups, i.e. primary and metastatic. A primary brain tumor is often described as "low grade" or "high grade." A low-grade tumor generally grows slowly, but it can turn into a high-grade tumor, whereas a high-grade tumor is more likely to grow faster. Secondary brain tumors, also called brain metastases, are much more common than primary tumors in adults. The most common types of primary tumors in adults are meningiomas and astrocytomas, such as glioblastomas. In children, the most common types of brain tumors include medulloblastomas, low-grade astrocytomas (pilocytic), ependymomas, craniopharyngiomas, and brainstem gliomas. All types of brain tumors produce symptoms that vary depending on the part of the brain involved. These symptoms may include headaches, seizures, problems with vision, vomiting and mental changes. Even though the exact cause of most brain tumors is unknown, some uncommon risk factors include exposure to chemicals, radiation, and family history of brain tumors.
Brain Cancer Diagnosis
Most brain tumors are not diagnosed until after symptoms appear. In general, diagnosing a brain tumor usually begins with magnetic resonance imaging (MRI). Once MRI shows a tumor in the brain, the most common way to determine the type of brain tumor is to look at the results from a tissue sample after a biopsy or surgery. Blood tests are also done to help diagnose certain brain tumors such as pituitary gland, pineal region and germ cell tumors.
Sophisticated imaging techniques are used to pinpoint brain tumors. Diagnostic tools used for this purpose include computed tomography (CT or CAT scan) and MRI. Other MRI sequences can help the surgeon plan the resection of the tumor based on the location of the normal nerve pathways of the brain. Intraoperative MRI is also used during surgery to guide tissue biopsies and tumor removal. Magnetic resonance spectroscopy (MRS) is used to examine the tumor's chemical profile and determine the nature of the lesions seen on the MRI. Positron emission tomography (PET scan) can help detect recurring brain tumors.
Brain Cancer Treatment
Treatment options for brain cancers include surgery, radiation therapy, chemotherapy, and targeted therapy. The treatment options and recommendations depend on several factors like the size, type, and grade of the tumor, whether the tumor is putting pressure on vital parts of the brain, if the tumor has spread to other parts of the CNS or the body, the possible side effects and finally, the treatment preferences and overall health of the patient.
For a low-grade brain tumor, surgery may be the only treatment needed, especially if all of the tumor can be removed. If there is visible tumor remaining after surgery, radiation therapy and chemotherapy may be used. For higher-grade tumors, treatment usually begins with surgery, followed by radiation therapy and chemotherapy.
Brain Cancer Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incidence of Primary Brain Tumors, Grade-specific Incidence of Brain Tumors, Type-specific Incidence of Brain Tumors, Gender-specific Incidence of Brain Tumors, and Age-specific Incidence of Brain Tumors in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.
Key Findings
This section provides glimpse of the brain cancer epidemiology in the 7MM.
- The total incident population of Primary Brain Tumors in the 7 major markets was estimated to be 60,103 in 2020. In case of Primary Brain Tumors patients in the United States, the incident cases were 23,056 in 2020.
- The total incident population of Primary Brain Tumors in the 7 MM is expected to increase at a CAGR of 0.88% during the forecast period 2021-2030.
- Brain Tumors can be divided into, Low-grade (I and II) and High-grade (III and IV) tumors. In the United States, these cases were 6,917 and 16,139, respectively, in 2020.
- In the United States, the incidence of Brain Tumors was 13,534 in males and 9,522 in females, in 2020.
- There are many types of Brain Tumors; however, the types that are considered in this report include Pilocytic Astrocytoma, Diffuse Astrocytoma, Anaplastic Astrocytoma, Oligodendrogliomas, Glioblastoma Multiforme (GBM), Diffuse midline glioma (Earlier called as DIPG) , and others, which represented 1,383, 3,458, 1,844, 1,614, 11,989, 853, and 1,914 cases, respectively, in the United States, in 2020.
- In the United States, the highest incidence of Brain Tumors was in the age-group 40-64 years with 10,144 cases, followed by the age-group ≥65 years with 8,992 cases in 2020. The lowest incidence of Brain Tumors was reorted in the age-group 0-39 years with 3,919 cases in 2020.
- In the EU5 countries, the incident population of Primary Brain Tumors was maximum in Italy with 7,320 cases, followed by the Germany with 7,173 cases in 2020. While, the United Kingdom accounted for the lowest incident population of the indication with 4,433 cases in 2020.
- As per Delvelnsight's analysis, Japan had 8,132 incident cases of Primary Brain Tumors in 2020.
Country Wise- Brain Cancer Epidemiology
The epidemiology segment also provides the brain cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Brain Cancer Drug Chapters
The drug chapter segment of the brain cancer report encloses the detailed analysis of brain cancer marketed drugs and mid and late stage pipeline drugs. It also helps to understand the brain cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Brain Cancer Marketed Drugs
Avastin: Genentech
Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors, which normalizes the tumor vasculature and inhibits the formation of new tumor vasculature, thereby preventing the tumor growth. VEGF is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent.
Product details in the report.....
Temodar/Temodal: Merck
The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine, used for the treatment of newly diagnosed glioblastoma multiforme and refractory anaplastic astrocytoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets selectively tumoral tissues; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly. Temodar/Temodal was initially commercialized by Merck in the different countries, whereas Baxter Oncology was responsible for the manufacture of Temodar injection. However, due to patent expiry, the market holds the generic version of the drug. Recently, the gel formulation of Temozolomide has also been approved by Double Bond Pharmaceuticals.
Product details in the report.....
Gliadel Wafers: Arbor Pharmaceuticals
Gliadel Wafer (polifeprosan 20 with carmustine implant) is an alkylating drug indicated to treat newly-diagnosed high-grade glioma (HGG) as an adjunct to surgery and radiation and rGBM as an adjunct to surgery. Applied directly into the resection cavity, Gliadel Wafer is a local chemotherapeutic agent. Local delivery of chemotherapy is a single procedure that coincides with surgical resection and delivers significant dose concentrations of carmustine, which circumvents the need for crossing blood-brain barrier.
Product details in the report.....
Delytact: Daiichi Sankyo
Delytact (Teserpaturev, formerly DS-1647) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) developed by Daiichi Sankyo. Teserpaturev has triple mutations within the viral genome that cause augmented and selective replication in cancer cells and enhanced induction of antitumor immune response while retaining the high safety features. Teserpaturev is currently the first third generation oncolytic HSV-1 to be tested in humans. Teserpaturev received Orphan Drug Designation in 2017 and Sakigake Designation in 2016 from the Japan MHLW for the treatment of patients with malignant glioma. The first-in-human phase I/IIa trial and the investigator-initiated phase II clinical trial were conducted by University of Tokyo in patients with glioblastoma. In June 2021 Daiichi Sankyo announced that it has received conditional and time-limited approval from the Japan MHLW for Delytact, for the treatment of patients with malignant glioma. Continued approval for this indication may be contingent upon verification and description of clinical benefit and safety in a post-market comparative clinical study
Product details in the report.....
Brain Cancer Emerging Drugs
Eflornithine + Lomustine: Orbus Therapeutics
Eflornithine (α-difluoromethylornithine or DFMO) is an orally bioavailable small molecule and an irreversible inhibitor of ornithine decarboxylase (ODC) that presents a cytostatic effect in rapidly dividing cells. ODC is a key enzyme in the first step of the synthesis of polyamines, converting ornithine to putrescine and it is known that ODC is up-regulated in certain types of cancer. Eflornithine has already been approved by the FDA in intravenous form to treat patients with African trypanosomiasis (sleeping sickness) and was subsequently approved by FDA in a topical form to treat patients with excessive facial hair, or hirsutism. Historically, the company has investigated this drug in several combinations for recurrent malignant gliomas, AA and anaplastic oligoastrocytoma, as well as for recurrent or progressive gliomas.
Product details in the report.....
Ofranergene obadenovec (VB-111): VBL Therapeutics
Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that is being developed by VBL Therapeutics to treat a wide range of solid tumors such as GBM. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. In patients, improvement has been experienced in post treatment fever suggesting that VB-111's mode of action involves induction of a tumor-directed immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the proangiogenic factors secreted by the tumor. VB-111 is the first agent, based on transcriptional targeting of tumor endothelium, to be assessed in a clinical trial. The drug is being investigated using VBL's proprietary Vascular Targeting System (VTS) platform Technology to target endothelial cells in the tumor vasculature for cancer therapy, which is conveniently administered as an intravenous infusion once every 2 months.
Product details in the report.....
Regorafenib: Bayer
Regorafenib is an oral multi-kinase inhibitor that potently blocks multiple protein kinases involved in tumor angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), metastasis (VEGFR3, PDGFR, FGFR) and tumor immunity (CSF1R). It is an inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. Regorafenib is already approved under the brand name Stivarga in more than 90 countries, including the US, countries of the European Union, China and Japan for metastatic colorectal cancer, metastatic gastrointestinal stromal tumors and hepatocellular carcinoma.
Product details in the report.....
Durvalumab (MEDI4736): MedImmune
Durvalumab is an investigational human monoclonal antibody directed against the programmed cell death ligand 1 (PD-L1) protein in development by MedImmune. Signals from PD-L1 help tumors avoid detection by the immune system. Durvalumab blocks these signals, countering the tumor's immune-evading strategies. The antibody belongs to an emerging class of immunotherapies commonly referred to as checkpoint inhibitors; because they remove checks, the body places on immune activation. The mechanism of action of Durvalumab includes PD-L1 expression on tumor cells and tumor-associated immune cells in the tumor microenvironment that can be induced by inflammatory signals and cytokines. PD-L1 blocks T-cell function and activation by interacting with PD-1 and CD80 (B7.1) and reduces cytotoxic T-cell activity, proliferation, and cytokine production.
Product details in the report.....
Tasadenoturev (DNX-2401): DNAtrix
DNX-2401, explored by DNAtrix, is oncolytic immunotherapy designed to fulfill the dual requirements of high potency and safety. In order to achieve this, two stable genetic changes in the adenovirus genome were engineered that cause it to replicate selectively in retinoblastoma (Rb) pathway deficient cells and infect tumor cells efficiently. Results from preclinical and clinical studies indicate that DNX-2401 replicates in human tumors, elicits tumor necrosis, triggers intratumoral immune cell infiltration and can lead to long term tumor destruction. DNAtrix is planning a Phase III study to investigate the drug as a monotherapy for glioblastoma patients. <>Additionally, the company is also evaluating DNX-2401 in a Phase I study for the treatment of diffuse intrinsic pontine glioma, where the company received FDA Fast Track and Rare Pediatric Disease designations.
Product details in the report.....
ONC201: Oncoceutics/ Chimerix
A novel therapeutic intervention of Imipridone class is in development by Oncoceutics, i.e., ONC201, which is a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that can penetrate the blood-brain-barrier effectively. ONC201 engages proven anticancer pathways that lead to apoptosis in cancer cells. It is a small molecule originally identified as TNF-related apoptosis-inducing ligand (TRAIL)-inducing compound. It has a unique ability to induce expression of both pro-death ligand TRAIL and its receptor DR5 through the engagement of the cellular integrated stress response (ISR) pathway. ONC201 has demonstrated single-agent efficacy in eliminating cancer stem cells CSCs in glioblastoma, colorectal, and prostate cancer models.
Product details in the report.....
Selinexor (KPT-330): Karyopharm Therapeutics
Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export/SINE compound in development by Karyopharm Therapeutics. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function; this is supposed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. The drug has been approved with a brand name Xpovio for patients in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Product details in the report.....
Everolimus (RAD001): Novartis
Everolimus (RAD001) is an orally administered drug that works by interrupting the PI3K/Akt/mTOR cell-signaling pathway that is overactive in certain tumors. The drug inhibits explicitly mTOR, a protein that may help many tumors grow, thereby stopping the hyperactivation. It binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of mTOR kinase activity. The drug has already been approved as an anti-cancer agent for other tumor types and is currently being investigated to treat low-grade gliomas..
Product details in the report.....
PVSRIPO: Istari Oncology
PVSRIPO is novel viral immunotherapy based on the Sabin type-1 polio vaccine and genetically modified so it is fully neuro-incompetent and cannot harm healthy cells. It has a natural affinity for CD155 antigens, which are specific surface markers abundant on glioblastoma cells. CD155 is also expressed on antigen-presenting cells such as dendritic cells and macrophages. Unlike cancer cells that have a weakened antiviral response, macrophages and dendritic cells exposed to PVSRIPO can limit viral replication and can engage T-cells. Thus, PVSRIPO targets tumors with two primary mechanisms; first, direct damage to and killing of cancerous cells, and second, engaging innate and adaptive antitumor immune responses via sublethal infection of antigen-presenting cells in the tumor, which unleashes an inflammatory cascade resulting in sustained systemic antitumor immunity.
PVSRIPO has the potential to be used as a treatment against a multitude of cancers as many diverse tumor cells exhibit abundant surface expression of CD155. It has been granted Breakthrough Therapy designation and Orphan Status by the FDA in rGBM. The company is currently conducting multiple Phase II and I trials for rGBM in association with the Duke University.
Product details in the report.....
G207: Treovir
G207 is an oncolytic herpes simplex virus (HSV) engineered to infect only tumor cells. When infused into a tumor, the virus enters the tumor cells and replicates, eventually killing them. In the process, G207 releases viral progeny that infects and kills nearby tumor cells. G207 is engineered so that it selectively infects and kills tumor cells leaving healthy cells unharmed. Death of infected tumor cells releases G207 that spreads to infect additional tumor cells and to elicit a florid T-cell immune-related inflammatory response within the tumor. It is believed that the patient's immune response is a major basis for the antitumor efficacy of G207. Furthermore, as demonstrated in the Phase I study for the first time, G207 induces a strong local immune response to harness the body's immune system to further fight against the tumor cells. In May 2019, the FDA granted Orphan Drug designation to G207 for the treatment of medulloblastoma and primitive neuroectodermal brain tumor; it had previously received an orphan designation for GBM. In addition, the FDA awarded the drug a Fast Track designation in August 2020.
The ongoing Phase I trials are being conducted by the University of Alabama, Birmingham. The Phase II trial in children with recurrent HGG is set to begin in December 2021 by the University in collaboration with Treovir, which is expected to support the market approval of G207 to treat pediatric recurrent HGGs.
Product details in the report.....
Brain Cancer Market Outlook
Brain tumors are solid tumors arising from transformed cells of the brain. These tumors can be of low grade (Grade I and II) or high grade (Grade III and IV). Of these, high grade tumours tend to grow rapidly and spread faster than tumours of a lower grade.
Though, there are several subtypes of these tumours but DelveInsight has only considered the most common ones for which certain pipeline therapies are being investigated.
Brain tumors, specifically HGGs are very difficult tumors to treat due to the problems in completely removing the tumor and their resistance to radiotherapy and chemotherapy. As there is no ideal treatment, therefore it is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for the indication may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. The best treatment options for each person depends on many factors like the size and location of the tumor, the extent to which the tumor has grown into the surrounding normal brain tissues, and the affected person's age and overall health.
Other than these current therapies, the brain tumor pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which is yet to be launched. The pipeline involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) along with four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.
The potential candidates with promising results in late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), Eflornithine (Orbus Therapeutics) and Regorafenib (Bayer). Out of these, Orbus therapeutics' Eflornithine is the only therapy being investigated solely for recurrent anaplastic astrocytoma (AA) while a majority of therapies in the pipeline are being investigated for GBM.
Followed by the late-stage products, a wide array of mid-stage or phase II promising interventions are expected to be launched in the near future in the market which include <>Durvalumab (MEDI4736; MedImmune), Tasadenoturev (DNX-2401; DNAtrix), ONC201 (Chimerix), Selinexor (KPT-330; Karyopharm Therapeutics), VBI-1901 (VBI Vaccines), Paxalisib (Kazia Therapeutics), AV-GBM-1 (Aivita Biomedical), MDNA55 (Medicenna Therapeutics), VAL-083 (Dianhydrogalactitol; DelMar Pharmaceuticals), ITI-1000 (Immunomic Therapeutics), Everolimus (Novartis) and INO-5401 + INO-9012 + Cemiplimab (Inovio Pharmaceuticals).
Key Findings
This section includes a glimpse of the Brain Tumor 7MM market.
- The market size of Brain Tumors in the seven major markets was estimated to be USD 2,784 Million in 2020, which is expected to show a positive growth at a CAGR of 1.11% during the study period 2018-2030.
- The United States Accounts For The largest market size Of Brain Tumors throughout the study period of 2018-2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 1447 Million in 2020.
- Among the EU5 countries, Germany had the highest market size with USD 249 Million in 2020, while United Kingdom and Spain had the lowest market size with USD 154 Million in 2020.
- The Japan Brain Tumors market accounted for USD 332 Million in 2020.
The United States Market Outlook
This section provides the total Brain Tumor market size and market size by therapies in the United States.
EU-5 Market Outlook
The total Brain Tumor market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Brain Tumor market size and market size by therapies in Japan are provided.
Brain Cancer Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the brain cancer market or expected to get launched in the market during the study period 2018-2030. The analysis covers brain cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Brain Cancer Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for brain cancer emerging therapies.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the brain cancer market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of brain cancer, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the brain cancer epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for brain cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of brain cancer market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM brain cancer market.
Report Highlights
- In the coming years, brain cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence brain cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Delvelnsight has analysed incident population of Primary Brain Tumors in the 7MM which suggests that the cases of Primary Brain Tumors will increase during the forecast period of 2021-2030.
- In addition, gender-specific incidence of Brain Tumors was assessed as well. As per the analysis, Brain Tumors is slightly more incident in males than in females.
- The scope of the report also encompasses another major segment, i.e., grade-specific incidence brain cancer, wherein the number of patients suffering from Low-grade (I and II) and High-grade (III and IV) tumors was calculated.
- Age-specific data of Brain Tumors suggests that incidence of Brain Tumors in the US, was highest in the age group of 40-64 years, followed by ≥65 years and 0-39 years.
- There are many types of Brain Tumors; however, the types that are considered in this report include Pilocytic Astrocytoma, Diffuse Astrocytoma, Anaplastic Astrocytoma, Oligodendrogliomas, Glioblastoma Multiforme (GBM), Diffuse midline glioma (Earlier called as DIPG), and others.
- Currently, the first-line treatment involves Surgery ± Radiation Therapy/ Chemotherapy, Temozolomide+Radiation Therapy (RT) or Radiation Alone- Maintanance therapy, Temozolomide monotherapy and Gliadel Wafer Implant. While the second-line treatment for Brain Tumors includes Bevacizumab monotherapy, Bevacizumab Combination therapy, Temozolomide (Both as Combination and monotherapy), Gliadel Wafer Implant/Surgery and Other Systemic therapies (Concomitant and Adjuvant Chemotherapy agents)).
- Expected Launch of potential therapies, such as Bayer (Regorafenib), Diffusion Pharmaceuticals (Trans Sodium Crocetinate), VBL Therapeutics (Ofranergene obadenovec (VB-111)), AstraZeneca (Durvalumab), DNAtrix (Tasadenoturev (DNX-2401) + Pembrolizumab), Kintara Therapeutics (VAL-083 (Dianhydrogalactitol)), Chimerix (ONC201), KaryoPharma (Selinexor (KPT-330)), VBI Vaccines (VBI-1901), Kazia Therapeutics (Paxalisib (GDC-0084)), Aivita Biomedical (AV-GBM-1), Medicenna Therapeutics (MDNA55), Immunomic Therapeutics (pp65-shLAMP DC with GM-CSF (ITI-1000)), Inovio Pharmaceuticals (INO-5401+ INO-9012 + Cemiplimab (REGN2810)), Orbus Therapeutics (Eflornithine + Lomustine), Novartis (Everolimus (RAD001)), Treovir (G207) and Istari Oncology (PVSRIPO) may increase market size in the coming years, assisted by an increase in Brain Tumors incident population pool.
Brain Cancer Report Insights
- Patient Population
- Therapeutic Approaches
- Brain Cancer Pipeline Analysis
- Brain Cancer Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Brain Cancer Report Key Strengths
- Ten Years Forecast
- 7MM Coverage
- Brain Cancer Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Brain Cancer Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the brain cancer market share (%) distribution in 2018 and how it would look like in 2030?
- What would be the brain cancer total market size as well as market size by therapies across the 7MM during the forecast period (2021-2030)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest brain cancer market size during the forecast period (2021-2030)?
- At what CAGR, the brain cancer market is expected to grow at the 7MM level during the forecast period (2021-2030)?
- What would be the brain cancer market outlook across the 7MM during the forecast period (2021-2030)?
- What would be the brain cancer market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of brain cancer?
- What is the historical brain cancer patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of brain cancer at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Brain Cancer?
- Out of the above-mentioned countries, which country would have the highest incident population of brain cancer during the forecast period (2021-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the treatment of brain cancer along with the approved therapy?
- What are the current treatment guidelines for the treatment of brain cancer in the US and Europe?
- What are the brain cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of brain cancer?
- How many therapies are developed by each company for the treatment of brain cancer?
- How many emerging therapies are in the mid-stage and late stage of development for the treatment of brain cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the brain cancer therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for brain cancer and their status?
- What are the key designations that have been granted for the emerging therapies for brain cancer?
- What are the 7MM historical and forecasted market of brain cancer?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Brain Cancer.
- To understand the future market competition in the brain cancer market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for brain cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for brain cancer market.
- To understand the future market competition in the brain cancer market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Brain Cancer Market Overview at a Glance
- 3.1. Market Share by Current Therapies (%) Distribution of Brain Cancer
- 3.2. Market Share by Emerging Therapies (%) Distribution of Brain Cancer
4. Executive Summary of Brain Cancer
5. Key Events
6. SWOT Analysis
7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Types
- 7.2.1. Primary brain tumors
- 7.2.2. Secondary brain tumors
- 7.3. Symptoms
- 7.4. Causes and Risk factors
- 7.5. Prevention
- 7.6. Brain Tumor Grading
- 7.7. Clinical presentation
- 7.8. Biomarkers
- 7.9. Diagnosis
- 7.9.1. Neurological examination
- 7.9.2. Imaging tests
- 7.9.3. Lumbar puncture or spinal tap
- 7.9.4. Advanced genomic testing
- 7.9.5. Nuclear medicine bone scan
- 7.9.6. Angiography
- 7.9.7. Electroencephalography (EEG)
- 7.9.8. Evoked potentials
- 7.9.9. Brain biopsy
- 7.10. Diagnostic Guidelines for Adult Astrocytic and Oligodendroglial Gliomas by the European Association for Neuro-oncology (EANO)
8. Treatment
- 8.1. Radiation therapy
- 8.2. Surgery
- 8.3. Chemotherapy
- 8.4. Targeted therapy
- 8.5. Laser Thermal Ablation
- 8.6. Alternating Electric Field Therapy
- 8.7. Other Drug Treatments
- 8.8. Treatment of Brain Tumors by Type
- 8.8.1. Non-infiltrating (grade I) astrocytomas
- 8.8.2. Low-grade (grade II) infiltrating astrocytomas (Diffuse astrocytomas)
- 8.8.3. Intermediate-grade (grade III) gliomas (Anaplastic astrocytomas, anaplastic oligodendrogliomas)
- 8.8.4. Oligodendrogliomas
- 8.8.5. Ependymomas and anaplastic ependymomas
- 8.8.6. Meningiomas
- 8.8.7. Schwannomas (including acoustic neuromas)
9. National Comprehensive Cancer Network (NCCN) Guidelines for Central Nervous System Cancers (2020)
- 9.1. Molecular Testing Recommendations for Glioma
- 9.2. Recommendations for treatment of Grade I Gliomas
- 9.3. Recommendations for treatment of Grade II Infiltrative Supratentorial Astrocytoma/Oligodendroglioma
- 9.4. Recommendations for treatment of Anaplastic Gliomas and Glioblastomas
- 9.5. Recommendations for treatment of Brain Metastases
10. Neurological and vascular complications of primary and secondary brain tumors: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up (2020)
- 10.1. Recommendations for the management of brain edema
- 10.2. Recommendations for the management of seizures
- 10.3. Recommendations for the management of Neurocognitive impairment
- 10.4. Recommendations for the management of venous thromboembolism and stroke
11. NICE Guidelines: Brain tumors (primary) and brain metastases in adults (2018)
- 11.1. Investigation of glioma:
- 11.2. Management of glioma:
- 11.3. Investigation of suspected meningioma
- 11.4. Investigation of suspected brain metastases
- 11.5. Management of confirmed brain metastases
- 11.6. Care needs of people with brain tumors
- 11.7. Neuro-rehabilitation needs of people with brain tumors
12. Treatment Algorithm
13. Epidemiology and Patient Population
- 13.1. Key Findings
- 13.2. Epidemiology Methodology
- 13.3. 7MM Total Incidence of Primary Brain Tumors
- 13.4. Epidemiology of Brain Cancer
- 13.4.1. The United States
- 13.4.2. EU5
- 13.4.3. Japan
- 13.5. The United States
- 13.5.1. Total Incidence of Primary Brain Tumors in the United States
- 13.5.2. Grade-specific Incidence of Brain Tumors in the United States
- 13.5.3. Type-specific Incidence of Brain Tumors in the United States
- 13.5.4. Gender-specific Incidence of Brain Tumors in the United States
- 13.5.5. Age-specific Incidence of Brain Tumors in the United States
- 13.6. EU5
- 13.6.1. Total Incidence of Primary Brain Tumors in EU5
- 13.6.2. Grade-specific Incidence of Brain Tumors in EU5
- 13.6.3. Type-specific Incidence of Brain Tumors in EU5
- 13.6.4. Gender-specific Incidence of Brain Tumors in EU5
- 13.6.5. Age-specific Incidence of Brain Tumors in EU5
- 13.7. Japan
- 13.7.1. Total Incidence of Primary Brain Tumors in Japan
- 13.7.2. Grade-specific Incidence of Brain Tumors in Japan
- 13.7.3. Type-specific Incidence of Brain Tumors in Japan
- 13.7.4. Gender-specific Incidence of Brain Tumors in Japan
- 13.7.5. Age-specific Incidence of Brain Tumors in Japan
14. Organizations contributing towards Brain Cancer
15. Patient Journey
16. Marketed Drugs
- 16.1. Avastin: Genentech
- 16.1.1. Product Description
- 16.1.2. Regulatory Milestones
- 16.1.3. Other Development Activities
- 16.1.4. Safety and Efficacy
- 16.1.5. Product Profile
- 16.2. Temodar/Temodal: Merck
- 16.2.1. Product Description
- 16.2.2. Regulatory Milestones
- 16.2.3. Other Development Activities
- 16.2.4. Safety and Efficacy
- 16.2.5. Product Profile
- 16.3. Gliadel Wafers: Arbor Pharmaceuticals
- 16.3.1. Product Description
- 16.3.2. Regulatory Milestones
- 16.3.3. Other Development Activities
- 16.3.4. Safety and Efficacy
- 16.3.5. Product Profile
- 16.4. Delytact: Daiichi Sankyo
- 16.4.1. Product Description
- 16.4.2. Regulatory Milestones
- 16.4.3. Other Development Activities
- 16.4.4. Product Profile
17. Emerging Therapies
- 17.1. Key Competitors
- 17.2. Eflornithine + Lomustine: Orbus Therapeutics
- 17.2.1. Product Description
- 17.2.2. Clinical Development
- 17.2.3. Clinical Trials Information
- 17.2.4. Safety and Efficacy
- 17.3. Ofranergene obadenovec (VB-111): VBL Therapeutics
- 17.3.1. Product Description
- 17.3.2. Clinical Development
- 17.3.3. Clinical Trials Information
- 17.3.4. Safety and Efficacy
- 17.4. Trans Sodium Crocetinate: Diffusion Pharmaceuticals
- 17.4.1. Product Description
- 17.4.2. Clinical Development
- 17.4.3. Clinical Trials Information
- 17.4.4. Safety and Efficacy
- 17.5. Regorafenib: Bayer
- 17.5.1. Product Description
- 17.5.2. Clinical Development
- 17.5.3. Clinical Trials Information
- 17.5.4. Safety and Efficacy
- 17.6. Durvalumab (MEDI4736): MedImmune
- 17.6.1. Product Description
- 17.6.2. Clinical Development
- 17.6.3. Clinical Trials Information
- 17.6.3. Safety and Efficacy
- 17.7. Tasadenoturev (DNX-2401): DNAtrix
- 17.7.1. Product Description
- 17.7.2. Clinical Development
- 17.7.3. Clinical Trials Information
- 17.7.4. Safety and Efficacy
- 17.8. ONC201: Chimerix
- 17.8.1. Product Description
- 17.8.2. Clinical Development
- 17.8.3. Clinical Trials Information
- 17.8.3. Safety and Efficacy
- 17.9. Selinexor (KPT-330): Karyopharm Therapeutics
- 17.9.1. Product Description
- 17.9.2. Clinical Development
- 17.9.3. Clinical Trials Information
- 17.9.4. Safety and Efficacy
- 17.10. VBI-1901: VBI Vaccines
- 17.10.1. Product Description
- 17.10.2. Clinical Development
- 17.10.3. Clinical Trials Information
- 17.10.4. Safety and Efficacy
- 17.11. Paxalisib (GDC-0084): Kazia Therapeutics
- 17.11.1. Product Description
- 17.11.2. Clinical Development
- 17.11.3. Clinical Trials Information
- 17.11.4. Safety and Efficacy
- 17.12. AV-GBM-1: Aivita Biomedical
- 17.12.1. Product Description
- 17.12.2. Clinical Development
- 17.12.3. Clinical Trials Information
- 17.12.4. Safety and Efficacy
- 17.13. MDNA55: Medicenna Therapeutics
- 17.13.1. Product Description
- 17.13.2. Clinical Development
- 17.13.3. Clinical Trials Information
- 17.13.4. Safety and Efficacy
- 17.14. VAL-083 (Dianhydrogalactitol): Kintara Therapeutics
- 17.14.1. Product Description
- 17.14.2. Clinical Development
- 17.14.3. Clinical Trials Information
- 17.14.4. Safety and Efficacy
- 17.15. Pomalidomide: Bristol-Myers Squibb
- 17.15.1. Product Description
- 17.15.2. Clinical Development
- 17.15.3. Clinical Trials Information
- 17.15.3. Safety and Efficacy
- 17.16. LAM561 (2-OHOA): Laminar Pharmaceuticals
- 17.16.1. Product Description
- 17.16.2. Clinical Development
- 17.16.3. Clinical Trials Information
- 17.16.4. Safety and Efficacy
- 17.17. ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
- 17.17.1. Product Description
- 17.17.2. Clinical Development
- 17.17.3. Clinical Trials Information
- 17.17.4. Safety and Efficacy
- 17.18. Everolimus (RAD001): Novartis
- 17.18.1. Product Description
- 17.18.2. Clinical Development
- 17.18.3. Clinical Trials Information
- 17.18.4. Safety and Efficacy
- 17.19. INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals
- 17.19.1. Product Description
- 17.19.2. Clinical Development
- 17.19.3. Clinical Trials Information
- 17.19.4. Safety and Efficacy
- 17.2. G207: Treovir
- 17.20.1. Product Description
- 17.20.2. Clinical Development
- 17.20.3. Clinical Trials Information
- 17.20.4. Safety and Efficacy
- 17.21. PVSRIPO: Istari Oncology
- 17.21.1. Product Description
- 17.21.2. Clinical Development
- 17.21.3. Clinical Trials Information
- 17.21.4. Safety and Efficacy
18. Potential of Current Therapies and Emerging Therapies
19. Brain Cancer: Seven Major Market Analysis
- 19.1. Key Findings
- 19.2. Market Methodology
- 19.3. Total Market Size of Brain Tumor in the 7MM in USD Million (2018-2030)
- 19.4. Market Size of Brain Tumor by Therapies in the 7MM
- 19.5. Market Outlook
- 19.6. Key Market Forecast Assumptions
- 19.7. United States Market Size
- 19.7.1. Total Market Size of Brain Tumor in the United States
- 19.7.2. Market Size of Brain Tumor by Therapies in the United States
- 19.8. EU-5 Market Size
- 19.8.1. Total Market size of Brain Tumor in Europe
- 19.8.2. Market Size of Brain Tumor by Therapies in Europe
- 19.9. Japan
- 19.9.1. Total Market size of Brain Tumor in Japan
- 19.9.2. Market Size of Brain Tumor by Therapies in Japan
20. KOL Views
21. Market Drivers
22. Market Barriers
23. Unmet Needs
24. Reimbursement and Market Access
- 24.1. United States
- 24.2. Europe
- 24.3. Japan
25. Appendix
- 25.1. Bibliography
- 25.2. Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
List of Tables
- Table 1: Summary of Brain Cancer Market, and Epidemiology (2018-2030)
- Table 2: Key Events
- Table 3: WHO classification of Astrocytoma tumors
- Table 4: World Health Organization (WHO) Brain Tumor Grades
- Table 5: Clinical presentation of primary brain tumor by location
- Table 6: Molecular markers in CNS/ Brain tumors and their current clinical implications
- Table 7: Treatment choices after surgery or in case surgery is not possible for different kinds of meningiomas
- Table 8: 7MM Total Incidence of Primary Brain Tumors (2018-2030)
- Table 9: Total Incidence of Primary Brain Tumors in the United States (2018-2030)
- Table 10: Grade-specific Incidence of Brain Tumors in the United States (2018-2030)
- Table 11: Type-specific Incidence of Brain Tumors in the United States (2018-2030)
- Table 12: Gender-specific Incidence of Brain Tumors in the United States (2018-2030)
- Table 13: Age-specific Incidence of Brain Tumors in the United States (2018-2030)
- Table 14: Total Incidence of Primary Brain Tumors in EU5 (2018-2030)
- Table 15: Grade-specific Incidence of Brain Tumors in EU5 (2018-2030)
- Table 16: Type-specific Incidence of Brain Tumors in EU5 (2018-2030)
- Table 17: Gender-specific Incidence of Brain Tumors in EU5 (2018-2030)
- Table 18: Age-specific Incidence of Brain Tumors in EU5 (2018-2030)
- Table 19: Total Incidence of Primary Brain Tumors in Japan (2018-2030)
- Table 20: Grade-specific Incidence of Brain Tumors in Japan (2018-2030)
- Table 21: Type-specific Incidence of Brain Tumors in Japan (2018-2030)
- Table 22: Gender-specific Incidence of Brain Tumors in Japan (2018-2030)
- Table 23: Age-specific Incidence of Brain Tumors in Japan (2018-2030)
- Table 24: Recognized Establishments
- Table 25: Comparison of emerging drugs under development
- Table 26: Comparison of emerging drugs under development
- Table 27: Eflornithine + Lomustine, Clinical Trial Description, 2021
- Table 28: VB-111, Clinical Trial Description, 2021
- Table 29: Trans Sodium Crocetinate, Clinical Trial Description, 2021
- Table 30: Regorafenib, Clinical Trial Description, 2021
- Table 31: Durvalumab, Clinical Trial Description, 2021
- Table 32: Tasadenoturev (DNX-2401), Clinical Trial Description, 2021
- Table 33: ONC201, Clinical Trial Description, 2021
- Table 34: Selinexor (KPT-330), Clinical Trial Description, 2021
- Table 35: VBI-1901, Clinical Trial Description, 2021
- Table 36: Paxalisib (GDC-0084), Clinical Trial Description, 2021
- Table 37: AV-GBM-1, Clinical Trial Description, 2021
- Table 38: MDNA55, Clinical Trial Description, 2021
- Table 39: VAL-083 (Dianhydrogalactitol), Clinical Trial Description, 2021
- Table 40: Pomalidomide (CC-4047), Clinical Trial Description, 2021
- Table 41: 2-OHOA, Clinical Trial Description, 2021
- Table 42: pp65 DC Vaccine, Clinical Trial Description, 2021
- Table 43: Everolimus (RAD001), Clinical Trial Description, 2021
- Table 44: INO-5401+ INO-9012+ Cemiplimab (REGN2810), Clinical Trial Description, 2021
- Table 45: G207, Clinical Trial Description, 2021
- Table 46: PVSRIPO, Clinical Trial Description, 2021
- Table 47: Market Size of Brain Tumor in the 7MM in USD Million (2018-2030)
- Table 48: Market Size of Brain Tumor by therapies in the 7MM, in USD Million (2018-2030)
- Table 49: Key Market Forecast Assumptions for Regorafenib
- Table 50: Key Market Forecast Assumptions for Trans Sodium Crocetinate
- Table 51: Key Market Forecast Assumptions for VB-111
- Table 52: Key Market Forecast Assumptions for Durvalumab
- Table 53: Key Market Forecast Assumptions for DNX-2401 ± Pembrolizumab
- Table 54: Key Market Forecast Assumptions for ONC201
- Table 55: Key Market Forecast Assumptions for KPT-330
- Table 56: Key Market Forecast Assumptions for VBI-1901
- Table 57: Key Market Forecast Assumptions for Paxalisib
- Table 58: Key Market Forecast Assumptions for AV-GBM-1
- Table 59: Key Market Forecast Assumptions for VAL-083
- Table 60: Key Market Forecast Assumptions for ITI-1000
- Table 61: Key Market Forecast Assumptions for MDNA55
- Table 62: Key Market Forecast Assumptions for INO-5401+INO-9012 with cemiplimab
- Table 63: Key Market Forecast Assumptions for Eflornithine + Lomustine
- Table 64: Key Market Forecast Assumptions for Everolimus (RAD001)
- Table 65: Key Market Forecast Assumptions for G207 ± Radiation
- Table 66: Key Market Forecast Assumptions for PVSRIPO
- Table 67: Market Size of Brain Tumor by therapies in the US, in USD Million (2018-2030)
- Table 68: EU5 Market Size of Brain Tumor in USD Million (2018-2030)
- Table 69: Market Size of Brain Tumor by therapies in EU5, in USD Million (2018-2030)
- Table 70: Japan Market Size of Brain Tumor in USD Million (2018-2030)
- Table 71: Market Size of Brain Tumor by therapies in Japan, in USD Million (2018-2030)
List of Figures
- Figure 1: 7MM Total Incidence of Primary Brain Tumors (2018-2030)
- Figure 2: Total Incidence of Primary Brain Tumors in the United States (2018-2030)
- Figure 3: Grade-specific Incidence of Brain Tumors in the United States (2018-2030)
- Figure 4: Type-specific Incidence of Brain Tumors in the United States (2018-2030)
- Figure 5: Gender-specific Incidence of Brain Tumors in the United States (2018-2030)
- Figure 6: Age-specific Incidence of Brain Tumors in the United States (2018-2030)
- Figure 7: Total Incidence of Primary Brain Tumors in EU5 (2018-2030)
- Figure 8: Grade-specific Incidence of Brain Tumors in the EU5 (2018-2030)
- Figure 9: Type-specific Incidence of Brain Tumors in EU5 (2018-2030)
- Figure 10: Gender-specific Incidence of Brain Tumors in EU5 (2018-2030)
- Figure 11: Age-specific Incidence of Brain Tumors in EU5 (2018-2030)
- Figure 12: Total Incidence of Primary Brain Tumors in Japan (2018-2030)
- Figure 13: Grade-specific Incidence of Brain Tumors in Japan (2018-2030)
- Figure 14: Type-specific Incidence of Brain Tumors in Japan (2018-2030)
- Figure 15: Gender-specific Incidence of Brain Tumors in Japan (2018-2030)
- Figure 16: Age-specific Incidence of Brain Tumors in Japan (2018-2030)
- Figure 17: Market Size of Brain Tumor in the 7MM in USD Million (2018-2030)
- Figure 18: 7 MM Size of Brain Tumor by Current Therapies, in USD Million (2018-2030)
- Figure 19: 7MM Size of Brain Tumor by Emerging Therapies, in USD Million (2018-2030)
- Figure 20: Market Size of Brain Tumor in the US, USD Millions (2018-2030)
- Figure 21: Market Size of Brain Tumor in the US, USD Millions (2018-2030)
- Figure 22: Market Size of Brain Tumor by Current Therapies in the US, in USD Million (2018-2030)
- Figure 23: Market Size of Brain Tumor by Emerging Therapies in the US, in USD Million (2018-2030)
- Figure 24: Market Size of Brain Tumor in EU5, USD Million (2018-2030)
- Figure 25: EU5 Market Size of Brain Tumor by Current Therapies in USD Million (2018-2030)
- Figure 26: EU5 Market Size of Brain Tumor by Emerging Therapies in USD Million (2018-2030)
- Figure 27: Market Size of Brain Tumor in Japan, USD Million (2018-2030)
- Figure 28:Japan Market Size of Brain Tumor by Current Therapies in USD Million (2018-2030)
- Figure 29:Japan Market Size of Brain Tumor by Emerging Therapies in USD Million (2018-2030)
